In a significant milestone for type 2 diabetes care, Novo Nordisk has unveiled full results from its SOUL cardiovascular outcomes trial, confirming that oral semaglutide (14 mg) reduces the risk of major adverse cardiovascular events (MACE) by 14 per cent compared to placebo in adults with type 2 diabetes and existing cardiovascular and/or chronic kidney disease
For instance, a randomized controlled trial, Intravenous 0.9% sodium chloride therapy does not reduce the length of stay of alcohol-intoxicated patients in the emergency department by Siegfried RS Perez, et al., 2013, found no significant difference in the length of emergency department stay between patients receiving IV fluids and those under observation alone
Although its become so normalized for people to lose weight using GLP-1 many are suffering from its bizarre side effects, like Ozempic face, except for a woman named Alejandra Salomon
But the real kicker
Mace Scott, Chronos Body Health & Wellness Chronos patients dont just receive medication
Every compound that produces meaningful physiological effects will produce some reactions in some people